COVID-19 Immune Repertoire Sequencing

This concerns a single-center prospective interventional cohort study. Laboratory-confirmed COVID-19 patients will be asked to donate blood at at least two different timepoints. This will allow us to investigate T and B cell evolutions during the course of infection and recovery. The expected duration of the study is four months or the total duration of the SARS-CoV-2 circulation in Belgium (whichever is shortest).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID B Cell Corona Virus Infection Coronaviridae Infections Coronavirus Infections Infections Nidovirales Infections RDT RNA Virus Infections SARS-CoV 2 Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Universitairy hospital of Antwerp

Antwerp, Belgium

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

laboratory confirmed COVID-19 acute infection
be older than 18 years of age
be hospitalized at the UZA
willing and able to provide written informed consent by the participant or its legal representative (for instance in case of medical incapacitation)

Exclusion criteria

younger than 18 years old
Ambulatory patients

Treatment and study plan

Primary outcomes

provide proof-of-concept that (longitudinal) B cell repertoire mining allows identification of emerging virus specific B cell receptor variable regions.

Time frame: 4 months

Secondary outcomes

study evolutions in B and T cell repertoires to understand COVID-19 specific immune responses fundamentally.

Time frame: every 7 days during hospitalization a bloodsample is taken
clinical and epidemiological description of UZA hospitalized COVID-19 patients

Time frame: at hospitalization

Sponsors and collaborators

Lead sponsor

Institute of Tropical Medicine, Belgium

Other

Collaborators

University Hospital, Antwerp

Registry information

Acronym: IMSEQ

Important dates

Study start: 2020
Primary completion: 2021
Study completion: 2021
First posted: Apr 29, 2020
Registry last updated: Oct 2, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed